Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 24;25(21):11411.
doi: 10.3390/ijms252111411.

Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches

Affiliations
Review

Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches

Tudorita Gabriela Paranga et al. Int J Mol Sci. .

Abstract

IL-6 remains a key molecule of the cytokine storms characterizing COVID-19, exerting both proinflammatory and anti-inflammatory effects. Emerging research underscores the significance of IL-6 trans-signaling over classical signaling pathways, which has shifted the focus of therapeutic strategies. Additionally, the synergistic action of TNF-α and IFN-γ has been found to induce inflammatory cell death through PANoptosis, further amplifying the severity of cytokine storms. Long COVID-19 patients, as well as those with cytokine storms triggered by other conditions, exhibit distinct laboratory profiles, indicating the need for targeted approaches to diagnosis and management. Growing evidence also highlights the gut microbiota's crucial role in modulating the immune response during COVID-19 by affecting cytokine production, adding further complexity to the disease's immunological landscape. Targeted intervention strategies should focus on specific cytokine cutoffs, though accurate cytokine quantification remains a clinical challenge. Current treatment strategies are increasingly focused on inhibiting IL-6 trans-signaling, which offers promise for more precise therapeutic approaches to manage hyperinflammatory responses in COVID-19. In light of recent discoveries, this review summarizes key research findings on cytokine storms, particularly their role in COVID-19 and other inflammatory conditions. It explores emerging therapeutic strategies targeting cytokines like IL-6, TNF-α, and IFN-γ, while also addressing open questions, such as the need for better biomarkers to detect and manage cytokine storms. Additionally, the review highlights ongoing challenges in developing targeted treatments that mitigate hyperinflammation without compromising immune function, emphasizing the importance of continued research in this field.

Keywords: COVID-19; IFN-γ; IL-6; TNF-α; cytokine storm; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The role of IL-6 signaling in cytokine–microbiome interactions with consequences on immune response effectiveness and viral replication. For dysbiosis, the uppercase arrows indicate elevated values, while the lowercase arrow indicate a reduction in the specified bacterial species.

References

    1. Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020;383:2255–2273. doi: 10.1056/NEJMra2026131. - DOI - PMC - PubMed
    1. Karki R., Kanneganti T.-D. The “Cytokine Storm”: Molecular Mechanisms and Therapeutic Prospects. Trends Immunol. 2021;42:681–705. doi: 10.1016/j.it.2021.06.001. - DOI - PMC - PubMed
    1. Chatenoud L., Ferran C., Legendre C., Thouard I., Merite S., Reuter A., Gevaert Y., Kreis H., Franchimont P., Bach J.F. In Vivo Cell Activation following OKT3 Administration. Systemic Cytokine Release and Modulation by Corticosteroids. Transplantation. 1990;49:697–702. doi: 10.1097/00007890-199004000-00009. - DOI - PubMed
    1. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N. Engl. J. Med. 2006;355:1018–1028. doi: 10.1056/NEJMoa063842. - DOI - PubMed
    1. Paranga T.G., Pavel-Tanasa M., Constantinescu D., Plesca C.E., Petrovici C., Miftode I.-L., Moscalu M., Cianga P., Miftode E.G. Comparison of C-Reactive Protein with Distinct Hyperinflammatory Biomarkers in Association with COVID-19 Severity, Mortality and SARS-CoV-2 Variants. Front. Immunol. 2023;14:1213246. doi: 10.3389/fimmu.2023.1213246. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources